Literature DB >> 20422305

High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection.

Li-Shuai Qu1, Fei Jin, Xiao-Wu Huang, Xi-Zhong Shen.   

Abstract

A retrospective cohort study was conducted to identify risk factors for recurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. A total of 317 patients who had received curative resection of pathologically proven small HCC (< or = 3 cm in diameter) were analyzed to ascertain the factors affecting recurrence. The median follow-up period was 33.7 months. Cumulative recurrence rates at 1, 3, and 5 years after resection were 23.5%, 49.5%, and 65.5%, respectively. Male sex, alpha-fetoprotein (AFP) > or = 400 ng/mL, HBV DNA level > or = 4 log(10) copies/mL, prolonged prothrombin time, tumor size > or = 2 cm, microvascular invasion, absence of capsular formation, moderate/poor tumor differentiation, and absence of postoperative interferon-alpha (IFN-alpha) treatment were associated with increased cumulative risk of HCC recurrence. By multivariate analysis, HBV DNA level > or = 4 log(10) copies/mL (P < 0.001, hazard ratio (HR) 2.110), AFP > or = 400 ng/mL (P = 0.011, HR 1.574), microvascular invasion (P < 0.001, HR 1.767), and postoperative IFN-alpha treatment (P = 0.022, HR 0.562) remained to be independently associated with HCC recurrence. Those contributing to late recurrence (>2 years) were older age and HBV DNA level > or = 4 log(10) copies/mL. Patients with persistent HBV DNA level > or = 4 log(10) copies/mL at resection and follow-up had the highest recurrence risk (P < 0.001, HR 4.129). HBV DNA level > or = 4 log(10) copies/mL at the time of resection was the most important risk factor for recurrence. Postoperative IFN-alpha treatment significantly decreased the recurrence risk after resection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422305     DOI: 10.1007/s11605-010-1211-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  31 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma.

Authors:  T Utsunomiya; M Shimada; K I Taguchi; H Hasegawa; Y Yamashita; T Hamatsu; S I Aishima; K Sugimachi
Journal:  J Am Coll Surg       Date:  2000-03       Impact factor: 6.113

3.  Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study.

Authors:  Zhi Li Wang; Ping Liang; Bao Wei Dong; Xiao Ling Yu; De Jiang Yu
Journal:  J Gastrointest Surg       Date:  2007-10-18       Impact factor: 3.452

4.  Hepatocellular carcinoma in Central Europe: prognostic features and survival.

Authors:  M Schöniger-Hekele; C Müller; M Kutilek; C Oesterreicher; P Ferenci; A Gangl
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

5.  Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis.

Authors:  T Ohkubo; J Yamamoto; Y Sugawara; K Shimada; S Yamasaki; M Makuuchi; T Kosuge
Journal:  J Am Coll Surg       Date:  2000-12       Impact factor: 6.113

6.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

7.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

Authors:  Zofia von Marschall; Arne Scholz; Thorsten Cramer; Georgia Schäfer; Michael Schirner; Kjell Oberg; Bertram Wiedenmann; Michael Höcker; Stefan Rosewicz
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

8.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

9.  Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.

Authors:  Shuji Sumie; Ryoko Kuromatsu; Koji Okuda; Eiji Ando; Akio Takata; Nobuyoshi Fukushima; Yasutomo Watanabe; Masamichi Kojiro; Michio Sata
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

10.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

View more
  23 in total

1.  Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma.

Authors:  Young-Joo Jin; Young-Hwa Chung; Jeong A Kim; Won Hyung Park; Danbi Lee; Dong Dae Seo; Soo Hyung Ryu; Myoung Kuk Jang; Eunsil Yu; Young Joo Lee
Journal:  Dig Dis Sci       Date:  2012-07-10       Impact factor: 3.199

Review 2.  Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.

Authors:  Xiao-Jun Lin; Xiang-Ming Lao; Ming Shi; Sheng-Ping Li
Journal:  Dig Dis Sci       Date:  2016-04-22       Impact factor: 3.199

Review 3.  Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis.

Authors:  Yanming Zhou; Zhansai Zhang; Yanfang Zhao; Lupeng Wu; Bin Li
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

Review 4.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

5.  Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study.

Authors:  Yujing Xin; Xinyuan Zhang; Yi Yang; Yi Chen; Yanan Wang; Xiang Zhou; Xiao Li
Journal:  J Gastrointest Oncol       Date:  2021-12

6.  Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.

Authors:  Lan-Qing Yao; Zheng-Liang Chen; Zi-Han Feng; Yong-Kang Diao; Chao Li; Hai-Ying Sun; Jian-Hong Zhong; Ting-Hao Chen; Wei-Min Gu; Ya-Hao Zhou; Wan-Guang Zhang; Hong Wang; Yong-Yi Zeng; Han Wu; Ming-Da Wang; Xin-Fei Xu; Timothy M Pawlik; Wan Yee Lau; Feng Shen; Tian Yang
Journal:  Ann Surg Oncol       Date:  2022-02-22       Impact factor: 5.344

Review 7.  Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.

Authors:  Shoji Kubo; Shigekazu Takemura; Shogo Tanaka; Hiroji Shinkawa; Takayoshi Nishioka; Akinori Nozawa; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Yorihisa Urata
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

8.  Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease.

Authors:  Ji Hae Nahm; Hye Sun Lee; Haeryoung Kim; Sun Young Yim; Ji-Hyun Shin; Jeong Eun Yoo; Sang Hoon Ahn; Jin Sub Choi; Ju-Seog Lee; Young Nyun Park
Journal:  Liver Int       Date:  2021-03-25       Impact factor: 5.828

9.  Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.

Authors:  Zili Hu; Huilan Zeng; Jingyu Hou; Juncheng Wang; Li Xu; Yaojun Zhang; Minshan Chen; Zhongguo Zhou
Journal:  Viruses       Date:  2022-03-22       Impact factor: 5.818

10.  Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Ming-Da Wang; Chao Li; Lei Liang; Hao Xing; Li-Yang Sun; Bing Quan; Han Wu; Xin-Fei Xu; Meng-Chao Wu; Timothy M Pawlik; Wan Yee Lau; Feng Shen; Tian Yang
Journal:  Oncologist       Date:  2020-06-09       Impact factor: 5.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.